公开(公告)号：US20160244497A1

公开(公告)日：2016-08-25

申请号：US15007438

申请日：2016-01-27

Applicant: Amgen Inc.

Inventor： Kenneth W. WALKER ,  Colin V. Gegg, JR. ,  Randy I. Hecht ,  Edward J. Belouski ,  Yue-Sheng Li ,  Mark L. Michaels ,  Jing Xu ,  Murielle Marie Ellison

IPC: C07K14/50 ,  A61K47/48

CPC classification number: C07K14/50 ,  A61K38/00 ,  A61K47/60

Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。

公开(公告)号：US20130217625A1

公开(公告)日：2013-08-22

申请号：US13861348

申请日：2013-04-11

Applicant: Amgen Inc.

Inventor： Kenneth W. Walker ,  Colin V. Gegg, JR.

IPC: C07K14/78 ,  C07K14/435

CPC classification number: C07K14/78 ,  A61K47/60 ,  C07K14/43504 ,  C07K14/43522 ,  C07K14/524 ,  C07K16/18 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/35

Abstract: Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of IgG1, a PDZ domain, a thrombospondin repeat domain, an ubiquitin domain, a leucine-rich repeat domain, a villin headpiece HP35 domain, a villin headpiece HP76 domain, or a fragment or modification of any of these. Also disclosed are nucleic acids (e.g., DNA constructs) encoding the fusion protein, expression vectors and recombinant host cells for expression of the fusion protein, and pharmaceutical compositions containing the recombinant fusion protein and a pharmaceutically acceptable carrier, and method of producing a pharmacologically active recombinant fusion protein.

公开(公告)号：US20130209466A1

公开(公告)日：2013-08-15

申请号：US13861349

申请日：2013-04-11

Applicant: AMGEN INC.

Inventor： Kenneth W. WALKER ,  Colin V. Gegg, JR.

IPC: C07K16/18 ,  C07K14/435

CPC classification number: C07K14/78 ,  A61K47/60 ,  C07K14/43504 ,  C07K14/43522 ,  C07K14/524 ,  C07K16/18 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/35

Abstract: Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of IgG1, a PDZ domain, a thrombospondin repeat domain, an ubiquitin domain, a leucine-rich repeat domain, a villin headpiece HP35 domain, a villin headpiece HP76 domain, or a fragment or modification of any of these. Also disclosed are nucleic acids (e.g., DNA constructs) encoding the fusion protein, expression vectors and recombinant host cells for expression of the fusion protein, and pharmaceutical compositions containing the recombinant fusion protein and a pharmaceutically acceptable carrier, and method of producing a pharmacologically active recombinant fusion protein.

Abstract translation: 公开了包含重组融合蛋白的组合物，其包含药理活性蛋白质配偶体和人源的小的药理学无活性蛋白质结构域伴侣，例如但不限于第10纤连蛋白III结构域，SH3结构域，SH2结构域 ，IgG1的CH2结构域，PDZ结构域，血小板反应蛋白重复结构域，泛素结构域，富含亮氨酸的重复结构域，绒毛头部HP35结构域，绒毛头部HP76结构域，或任何这些的片段或修饰。 还公开了编码融合蛋白的核酸（例如，DNA构建体），用于表达融合蛋白的表达载体和重组宿主细胞，以及含有重组融合蛋白和药学上可接受的载体的药物组合物，以及产生药理学活性的方法 重组融合蛋白。